vs
FEDERAL AGRICULTURAL MORTGAGE CORP（AGM）与Apellis Pharmaceuticals, Inc.（APLS）财务数据对比。点击上方公司名可切换其他公司
Apellis Pharmaceuticals, Inc.的季度营收约是FEDERAL AGRICULTURAL MORTGAGE CORP的1.9倍（$199.9M vs $107.5M），FEDERAL AGRICULTURAL MORTGAGE CORP同比增速更快（6.1% vs -5.9%），过去两年Apellis Pharmaceuticals, Inc.的营收复合增速更高（7.7% vs 7.1%）
联邦农业抵押贷款公司（又称Farmer Mac）是由美国国会1988年依据《1987年农业信贷法案》设立、由股东持股的联邦特许企业，核心业务是搭建农业不动产及住房抵押贷款的二级市场，提升农业领域的信贷流动性，为农户、牧场主及乡村社区提供长期稳定的信贷支持。
Apellis Pharmaceuticals是一家临床阶段生物制药企业，专注于开发调节补体系统的靶向疗法，适应症覆盖年龄相关性黄斑变性继发地图样萎缩等眼科疾病、罕见血液病及自身免疫性疾病，核心市场为美国及欧盟地区。
AGM vs APLS — 直观对比
营收规模更大
APLS
是对方的1.9倍
$107.5M
营收增速更快
AGM
高出12.1%
-5.9%
两年增速更快
APLS
近两年复合增速
7.1%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $107.5M | $199.9M |
| 净利润 | — | $-59.0M |
| 毛利率 | — | — |
| 营业利润率 | 56.3% | -25.6% |
| 净利率 | — | -29.5% |
| 营收同比 | 6.1% | -5.9% |
| 净利润同比 | — | -62.2% |
| 每股收益（稀释后） | $3.69 | $-0.40 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AGMAPLS
| Q4 25 | $107.5M | $199.9M | ||
| Q3 25 | $104.0M | $458.6M | ||
| Q2 25 | $102.6M | $178.5M | ||
| Q1 25 | $94.3M | $166.8M | ||
| Q4 24 | $101.3M | $212.5M | ||
| Q3 24 | $90.3M | $196.8M | ||
| Q2 24 | $89.9M | $199.7M | ||
| Q1 24 | $93.7M | $172.3M |
净利润AGMAPLS
| Q4 25 | — | $-59.0M | ||
| Q3 25 | $55.0M | $215.7M | ||
| Q2 25 | $54.8M | $-42.2M | ||
| Q1 25 | $49.7M | $-92.2M | ||
| Q4 24 | $56.5M | $-36.4M | ||
| Q3 24 | $49.8M | $-57.4M | ||
| Q2 24 | $47.1M | $-37.7M | ||
| Q1 24 | $53.7M | $-66.4M |
营业利润率AGMAPLS
| Q4 25 | 56.3% | -25.6% | ||
| Q3 25 | 64.1% | 48.7% | ||
| Q2 25 | 63.8% | -18.6% | ||
| Q1 25 | 66.9% | -50.0% | ||
| Q4 24 | 67.5% | -12.3% | ||
| Q3 24 | 69.0% | -24.0% | ||
| Q2 24 | 65.9% | -14.7% | ||
| Q1 24 | 72.8% | -36.0% |
净利率AGMAPLS
| Q4 25 | — | -29.5% | ||
| Q3 25 | 52.9% | 47.0% | ||
| Q2 25 | 53.4% | -23.6% | ||
| Q1 25 | 52.6% | -55.3% | ||
| Q4 24 | 55.8% | -17.1% | ||
| Q3 24 | 55.2% | -29.2% | ||
| Q2 24 | 52.4% | -18.9% | ||
| Q1 24 | 57.4% | -38.5% |
每股收益（稀释后）AGMAPLS
| Q4 25 | $3.69 | $-0.40 | ||
| Q3 25 | $4.44 | $1.67 | ||
| Q2 25 | $4.48 | $-0.33 | ||
| Q1 25 | $4.01 | $-0.74 | ||
| Q4 24 | $4.62 | $-0.30 | ||
| Q3 24 | $3.86 | $-0.46 | ||
| Q2 24 | $3.68 | $-0.30 | ||
| Q1 24 | $4.28 | $-0.54 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $466.2M |
| 总债务越低越好 | $30.8B | — |
| 股东权益账面价值 | $1.7B | $370.1M |
| 总资产 | $35.4B | $1.1B |
| 负债/权益比越低杠杆越低 | 17.93× | — |
8季度趋势，按日历期对齐
现金及短期投资AGMAPLS
| Q4 25 | — | $466.2M | ||
| Q3 25 | — | $479.2M | ||
| Q2 25 | — | $370.0M | ||
| Q1 25 | — | $358.4M | ||
| Q4 24 | — | $411.3M | ||
| Q3 24 | $842.1M | $396.9M | ||
| Q2 24 | $923.0M | $360.1M | ||
| Q1 24 | $745.1M | $325.9M |
总债务AGMAPLS
| Q4 25 | $30.8B | — | ||
| Q3 25 | $29.2B | — | ||
| Q2 25 | $28.9B | — | ||
| Q1 25 | $28.0B | — | ||
| Q4 24 | $27.5B | — | ||
| Q3 24 | $27.2B | — | ||
| Q2 24 | $26.8B | — | ||
| Q1 24 | $26.8B | $93.1M |
股东权益AGMAPLS
| Q4 25 | $1.7B | $370.1M | ||
| Q3 25 | $1.7B | $401.2M | ||
| Q2 25 | $1.5B | $156.3M | ||
| Q1 25 | $1.5B | $164.2M | ||
| Q4 24 | $1.5B | $228.5M | ||
| Q3 24 | $1.5B | $237.1M | ||
| Q2 24 | $1.5B | $264.3M | ||
| Q1 24 | $1.5B | $266.7M |
总资产AGMAPLS
| Q4 25 | $35.4B | $1.1B | ||
| Q3 25 | $33.4B | $1.1B | ||
| Q2 25 | $33.0B | $821.4M | ||
| Q1 25 | $31.8B | $807.3M | ||
| Q4 24 | $31.3B | $885.1M | ||
| Q3 24 | $30.6B | $901.9M | ||
| Q2 24 | $30.2B | $904.5M | ||
| Q1 24 | $29.8B | $831.9M |
负债/权益比AGMAPLS
| Q4 25 | 17.93× | — | ||
| Q3 25 | 17.31× | — | ||
| Q2 25 | 18.70× | — | ||
| Q1 25 | 18.39× | — | ||
| Q4 24 | 18.48× | — | ||
| Q3 24 | 18.60× | — | ||
| Q2 24 | 17.87× | — | ||
| Q1 24 | 18.11× | 0.35× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $80.1M | $-14.2M |
| 自由现金流经营现金流 - 资本支出 | — | $-14.3M |
| 自由现金流率自由现金流/营收 | — | -7.1% |
| 资本支出强度资本支出/营收 | 0.0% | 0.1% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $45.0M |
8季度趋势，按日历期对齐
经营现金流AGMAPLS
| Q4 25 | $80.1M | $-14.2M | ||
| Q3 25 | $74.2M | $108.5M | ||
| Q2 25 | $-47.7M | $4.4M | ||
| Q1 25 | $-49.8M | $-53.4M | ||
| Q4 24 | $612.6M | $19.4M | ||
| Q3 24 | $-44.4M | $34.1M | ||
| Q2 24 | $56.1M | $-8.3M | ||
| Q1 24 | $233.3M | $-133.0M |
自由现金流AGMAPLS
| Q4 25 | — | $-14.3M | ||
| Q3 25 | — | $108.3M | ||
| Q2 25 | — | $4.4M | ||
| Q1 25 | — | $-53.4M | ||
| Q4 24 | $607.4M | $19.3M | ||
| Q3 24 | $-44.4M | — | ||
| Q2 24 | $52.6M | $-8.4M | ||
| Q1 24 | $231.7M | $-133.3M |
自由现金流率AGMAPLS
| Q4 25 | — | -7.1% | ||
| Q3 25 | — | 23.6% | ||
| Q2 25 | — | 2.5% | ||
| Q1 25 | — | -32.0% | ||
| Q4 24 | 599.8% | 9.1% | ||
| Q3 24 | -49.2% | — | ||
| Q2 24 | 58.5% | -4.2% | ||
| Q1 24 | 247.3% | -77.3% |
资本支出强度AGMAPLS
| Q4 25 | 0.0% | 0.1% | ||
| Q3 25 | 0.0% | 0.0% | ||
| Q2 25 | 0.0% | 0.0% | ||
| Q1 25 | 0.0% | 0.0% | ||
| Q4 24 | 5.2% | 0.0% | ||
| Q3 24 | 0.1% | 0.0% | ||
| Q2 24 | 4.0% | 0.0% | ||
| Q1 24 | 1.7% | 0.2% |
现金转化率AGMAPLS
| Q4 25 | — | — | ||
| Q3 25 | 1.35× | 0.50× | ||
| Q2 25 | -0.87× | — | ||
| Q1 25 | -1.00× | — | ||
| Q4 24 | 10.84× | — | ||
| Q3 24 | -0.89× | — | ||
| Q2 24 | 1.19× | — | ||
| Q1 24 | 4.34× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AGM
暂无分部数据
APLS
| Syfovre | $155.2M | 78% |
| Empaveli Pegcetacoplan | $35.1M | 18% |
| Licensing And Other Revenue | $9.6M | 5% |
